Recombinant factor VIIa (rFVIIa) after aortic valve replacement in a patient with osteogenesis imperfecta.
Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.
Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial.
Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair
Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with hemophilia and high titre of inhibitors to FVIII: experience of two cases.
Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery.
An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant Factor VII (Case Report)
Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa.
Orthopaedic outcome of total knee replacement in haemophilia A.
Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors.
Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa.
Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study.
Major surgery for a gastric cancer in a haemophilic with high inhibitor titre successfully performed by the use of recombinant FVIIa.
Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
Use of recombinant factor VIIa (NovoSeven®) to reduce postoperative bleeding after total hip arthroplasty in a patient with cirrhosis and thrombocytopenia.
Synthetic factor VIIa to treat dilutional coagulopathy during posterior spinal fusion in two children.
Prescribing Info - Questions - Drug Info - Links - PDA Software - Article Summaries - Slideshows - Review Articles - What's New
© Copyright 1999-2020 All Rights Reserved.